Coherus Oncology, Inc.CHRSNASDAQ
LOADING
|||
EV to Sales: Discounted Valuation
Trending lower, below historical average, structural decline.
Left:
||||
Enterprise value to sales ratio
Latest
1.13
↓ 98% below average
Average (9y)
72.95
Historical baseline
Range
High:397.88
Low:1.13
CAGR
-28.5%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | 1.13 | -57.9% |
| 2023 | 2.69 | -45.0% |
| 2022 | 4.89 | +32.4% |
| 2021 | 3.69 | +57.3% |
| 2020 | 2.35 | -33.9% |
| 2019 | 3.55 | -99.1% |
| 2018 | 397.88 | +40.0% |
| 2017 | 284.11 | +4575.7% |
| 2016 | 6.08 | -73.7% |
| 2015 | 23.10 | - |